Experimental evidence for the topical use of angiotensin-converting enzyme inhibitors in eye drops for eye ischemia treatment

Inhibition of Angiotensin-Converting Enzyme Reduces Cerebral Infarction Size in Experimental-Induced Focal Cerebral Ischemia in the Rat

Background: The role of Renin Angiotensin System (RAS) in ischemic/reperfusion (I/R) injuries is not fully elucidated. Furthermore, it is not clear whether inhibition of RAS by Angiotensin-Converting Enzyme (ACE) inhibitors has beneficial effects in terms of protecting the brain from I/R injuries. In this study enalapril is used as an ACE inhibitor to evaluate the role of RAS in I/R injuries in...

Is there a role for angiotensin-converting enzyme inhibitors in the treatment of chronic myocardial ischemia?

Perioperative Use of Angiotensin-Converting Enzyme Inhibitors

Since the introduction of the first angiotensin-converting enzyme inhibitor (ACEI), captopril, in 1981, ACEIs have become a mainstay of antihypertensive therapy. In addition to lowering blood pressure, there is overwhelming evidence that ACEIs (and angiotensin receptor blockers) provide end-organ protection independent of their blood pressure–lowering properties in diseases such as congestive h...

Angiotensin Converting Enzyme in Sarcoidosis

Angiotensin converting enzyme inhibitors.

The purpose of this brief review is to separate the characteristic properties and side effects attributable to the pharmacology of the whole class of angiotensin converting enzyme (ACE) inhibitors from those attributable to the chemical structure and kinetics of each particular ACE inhibitor. The former would be predictable and probably similar for all agents and, therefore, would be expected t...